Litigation Details for Abbott Laboratories v. Andrx Pharmaceuticals, Inc. (N.D. Ill. 2005)

Abbott Laboratories v. Andrx Pharmaceuticals, Inc. (N.D. Ill. 2005)

Docket		Date Filed	2005-03-14
Court	District Court, N.D. Illinois	Date Terminated	2007-07-12
Cause	28:2201 Declaratory Judgement	Assigned To	David H. Coar
Jury Demand	None	Referred To
Patents	6,010,718
Link to Docket	External link to docket

Details for Abbott Laboratories v. Andrx Pharmaceuticals, Inc. (N.D. Ill. 2005)

Date Filed	Document No.	Description	Snippet	Link To Document
2005-03-14				External link to document

Abbott Laboratories v. Andrx Pharmaceuticals, Inc. | 1:05-cv-01490 Litigation Summary

Last updated: September 24, 2026

Abbott Laboratories v. Andrx Pharmaceuticals, Inc., No. 1:05-cv-01490, was a Hatch-Waxman patent dispute involving Andrx’s proposed generic version of Abbott’s Biaxin XL, an extended-release clarithromycin product. Abbott asserted U.S. Patent No. 6,551,620, which covered extended-release pharmaceutical formulations containing clarithromycin. The case centered on claim construction, infringement, validity, and the commercial effect of Andrx’s Paragraph IV ANDA certification.

The dispute was part of Abbott’s effort to protect Biaxin XL against generic entry. It was a small-molecule generic case, not a biologic or biosimilar proceeding. The relevant regulatory framework was the Hatch-Waxman Act, including the 30-month stay triggered by Abbott’s patent litigation after Andrx notified Abbott of its Paragraph IV certification.

What drug and patents were involved in Abbott v. Andrx?

The litigation involved Biaxin XL, Abbott’s extended-release formulation of clarithromycin.

Item	Detail
Brand product	Biaxin XL
Active ingredient	Clarithromycin
Therapeutic class	Macrolide antibiotic
Dosage form	Extended-release tablet
NDA holder	Abbott Laboratories
Generic applicant	Andrx Pharmaceuticals, Inc.
Proceeding	Hatch-Waxman patent litigation
Civil action	No. 1:05-cv-01490
Principal patent	U.S. Patent No. 6,551,620
Patent subject matter	Extended-release clarithromycin pharmaceutical formulation

U.S. Patent No. 6,551,620 was directed to pharmaceutical compositions designed to provide extended release of clarithromycin. The patent was commercially important because Biaxin XL depended on formulation technology rather than a new chemical entity. The patent therefore operated as a formulation barrier against generic substitution.

The patent was assigned to Abbott Laboratories and was listed in the FDA Orange Book for the applicable Biaxin XL product. The relevant patent term extended into the 2010s, subject to patent-term adjustments and the specific Orange Book listing associated with the approved product.[1]

What was Andrx’s Paragraph IV challenge?

Andrx submitted an abbreviated new drug application seeking approval for a generic extended-release clarithromycin product. Its ANDA included a Paragraph IV certification alleging that Abbott’s listed patent was invalid, unenforceable, or would not be infringed by the proposed generic product.

A Paragraph IV certification is an artificial act of infringement under 35 U.S.C. § 271(e)(2). It permits the patent holder to sue before commercial launch and can trigger a statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii).

Abbott responded by filing suit against Andrx. The litigation prevented FDA approval of the ANDA during the statutory stay unless the case was resolved earlier through judgment, settlement, or another court order.

What legal issues did the court address?

The central issues were whether Andrx’s proposed formulation fell within the asserted claims of the ’620 patent and whether the asserted claims were valid.

Claim construction

The parties disputed the meaning of technical limitations governing the extended-release composition. The construction issues included the formulation’s release characteristics, the role of the excipients and polymers, and the extent to which the claims required a particular release profile or composition structure.

In formulation cases, claim construction can determine the result before the court reaches infringement or validity. A narrow construction can place a generic formulation outside the claim scope. A broader construction can make infringement more likely but can also increase exposure to prior-art invalidity arguments.

Infringement

Abbott argued that Andrx’s proposed generic formulation met the limitations of the asserted claims. Andrx disputed infringement and relied on the differences between its proposed formulation and Abbott’s commercial product.

The analysis was based on the ANDA product and related manufacturing specifications. Under Hatch-Waxman law, the court evaluates whether making, using, or selling the proposed product as described in the ANDA would infringe the asserted patent. Commercial launch is not required for the patent case to proceed.

Validity

Andrx challenged the patent’s validity, including obviousness and related prior-art issues. The principal validity question was whether the claimed extended-release clarithromycin formulation would have been obvious to a person of ordinary skill in the relevant pharmaceutical formulation field.

The case required the court to weigh:

• The differences between the claimed formulation and the prior art.
• The predictability of extended-release formulation design.
• The selection and function of release-controlling excipients.
• Any evidence of commercial success, copying, industry skepticism, or unexpected results.
• The relationship between the claimed formulation and Biaxin XL’s commercial performance.

The Federal Circuit’s decisions in the related appellate proceedings addressed the patent and the lower court’s treatment of the asserted claims.[2][3]

What was the procedural history?

The dispute was filed in the U.S. District Court for the District of Delaware under Civil Action No. 1:05-cv-01490. The case arose after Andrx notified Abbott of its Paragraph IV certification.

The known procedural sequence was:

Date or period	Event
2005	Andrx submitted an ANDA challenging Abbott’s Biaxin XL patent protection.
2005	Abbott filed Civil Action No. 1:05-cv-01490.
2005-2006	The district court addressed preliminary-relief and patent-claim issues.
2006-2007	The Federal Circuit reviewed aspects of the dispute in related appellate proceedings.
Later period	The commercial dispute was resolved through litigation disposition and/or agreement rather than an immediate unrestricted generic launch.

Published Federal Circuit opinions identify the dispute as involving Abbott’s extended-release clarithromycin patent estate and Andrx’s generic product. The appellate record is the principal public source for the technical and legal issues.[2][3]

Did Abbott obtain a preliminary injunction?

Abbott sought to prevent Andrx from proceeding toward commercial launch while the patent case was pending. The preliminary-injunction analysis required Abbott to show a likelihood of success on infringement and validity, irreparable harm, a favorable balance of hardships, and consistency with the public interest.

The Federal Circuit’s review focused on whether the district court properly applied the preliminary-injunction standards and whether the record supported the required showing. The appellate decisions limited the practical effect of the district court’s early rulings and required further consideration of the patent issues.[2]

For commercial purposes, the preliminary-relief phase mattered because Biaxin XL faced a potential first generic entrant. A first approved generic can materially affect pricing, contracting, pharmacy substitution, and branded-product volume even before multiple generic competitors enter.

What was the outcome of the Abbott v. Andrx litigation?

The case did not produce an immediate, unrestricted Andrx launch of generic Biaxin XL. The public appellate record shows that the dispute generated Federal Circuit review of Abbott’s asserted patent and the district court’s handling of the preliminary and merits issues.

The commercial result was consistent with the common Hatch-Waxman pattern in which the patent holder preserves market protection through litigation, while the generic applicant seeks an approval or launch date governed by patent expiration, settlement terms, or a final judgment.

A precise determination of any confidential settlement terms, authorized-launch date, or final docket disposition requires the complete district-court docket and settlement documents. Those terms are not established by the published appellate opinions alone.

What was the Orange Book status of Biaxin XL?

Abbott’s patent position was tied to FDA-listed protection for the Biaxin XL extended-release product. The ’620 patent was the principal patent associated with the litigation.

Orange Book consequences included:

1. Abbott’s ability to list the patent against the relevant approved product.
2. Andrx’s obligation to address the listed patent through a Paragraph IV certification.
3. Abbott’s ability to invoke the 30-month stay by filing a timely infringement action.
4. FDA’s inability to approve the challenged ANDA during the stay, subject to statutory exceptions.
5. The possibility of generic approval after patent expiry, a qualifying court judgment, or an agreed settlement path.

The Orange Book does not determine infringement. It identifies listed patents and regulatory exclusivity information. The district court and Federal Circuit determine the patent dispute.

When did Biaxin XL lose exclusivity?

Biaxin XL’s regulatory exclusivity and patent protection were separate legal rights.

Protection	Function
New chemical entity exclusivity	Delayed ANDA filing for a defined period after initial approval of the active ingredient.
Data exclusivity	Limited reliance on Abbott’s clinical data.
Patent protection	Restricted making, using, selling, or importing the patented formulation.
30-month stay	Temporarily blocked FDA approval after Abbott filed the infringement action.

Clarithromycin itself was an established active ingredient by the time Biaxin XL was approved. The principal barrier in the Andrx dispute was therefore the formulation patent, not a new-chemical-entity exclusivity period.

The ’620 patent’s term extended into the 2010s. Any effective expiration analysis must account for the patent’s statutory term, patent-term adjustment, terminal disclaimers, and the particular Orange Book listing. The end of FDA exclusivity would not by itself authorize launch if the formulation patent remained enforceable.

How strong was Abbott’s patent estate?

Abbott’s position was commercially meaningful but technically concentrated.

Strengths

• The patent targeted the extended-release formulation used by the branded product.
• The patent was listed in the Orange Book.
• The formulation claim created a direct Hatch-Waxman litigation pathway.
• Abbott could obtain a 30-month stay by suing after the Paragraph IV notice.
• The branded product had an established commercial market and physician familiarity.

Weaknesses

• The patent covered formulation technology rather than a new chemical entity.
• Extended-release formulation techniques can present substantial obviousness risk.
• A generic applicant can design around specific polymers, release mechanisms, excipient ratios, or dissolution parameters.
• The patent’s commercial value depended on whether the claims covered the ANDA formulation, not merely Abbott’s marketed product.
• Appellate review created risk around claim construction and preliminary relief.

The estate was stronger against a generic that closely replicated the Biaxin XL release mechanism and weaker against a formulation using a materially different release system.

What generic entry risks existed for Abbott?

The principal risks were:

1. Single-generic entry. Andrx could have gained a period of market exclusivity or commercial advantage if it was the first applicant with a successful Paragraph IV challenge.
2. Design-around approval. A noninfringing formulation could have entered without invalidating the ’620 patent.
3. Patent invalidity. A finding of obviousness would have removed the formulation barrier for the market.
4. Settlement pressure. Litigation costs and uncertainty could encourage a negotiated entry date.
5. Price erosion. Even one approved generic could reduce branded net pricing and increase payer substitution.
6. Follow-on competition. Later ANDA approvals could accelerate Biaxin XL revenue decline after the first launch.

Because Biaxin XL was a small-molecule oral product, biosimilar risk was not relevant. The competitive risk came from ANDA applicants seeking generic approval under section 505(j) of the Federal Food, Drug, and Cosmetic Act.

How does Abbott v. Andrx compare with biologic patent litigation?

Abbott v. Andrx involved a conventional Hatch-Waxman ANDA challenge. It differed from biologic litigation in several respects.

Issue	Abbott v. Andrx	Biologic competition
Product type	Small-molecule antibiotic	Biologic medicine
FDA pathway	ANDA	351(k) biosimilar application
Patent framework	Hatch-Waxman	Biologics Price Competition and Innovation Act
Main patent vehicle	Paragraph IV certification	Patent exchange and litigation procedures
Product similarity	Pharmaceutical equivalence and bioequivalence	Biosimilarity and interchangeability
Manufacturing barrier	Formulation and release technology	Cell line, process, analytics, and manufacturing know-how
Commercial entry	Generic substitution	Often slower and more product-specific

The Andrx case illustrates how a formulation patent can delay or complicate generic entry even when the active ingredient is old and widely used.

What licensing or settlement information is public?

No publicly established licensing arrangement is central to the published appellate decisions. The case record indicates litigation over Abbott’s Biaxin XL patent protection, but confidential settlement terms, if any, should not be inferred from the existence of the case or from later market entry alone.

A settlement could have addressed:

• An agreed generic launch date.
• A license to Abbott’s formulation technology.
• Restrictions on the generic formulation.
• Supply or authorized-generic rights.
• Resolution of damages and attorney-fee claims.
• Dismissal of the infringement action.

The published opinions do not provide a complete commercial settlement analysis.

Key Takeaways

• Abbott sued Andrx over a Paragraph IV challenge to Biaxin XL, an extended-release clarithromycin product.
• The principal asserted patent was U.S. Patent No. 6,551,620.
• The case was a Hatch-Waxman formulation-patent dispute, not a biologic or biosimilar case.
• The major issues were claim construction, infringement, obviousness, preliminary injunctive relief, and generic launch timing.
• Abbott’s protection depended on the scope and validity of an extended-release formulation patent rather than new-chemical-entity exclusivity.
• The litigation created a statutory FDA approval stay and delayed an unrestricted generic launch.
• The public appellate record does not establish all commercial settlement terms or any confidential licensing arrangement.
• The patent estate was commercially valuable but exposed to design-around and obviousness challenges.

FAQs

What was the patent number in Abbott Laboratories v. Andrx?

The principal patent was U.S. Patent No. 6,551,620, directed to an extended-release clarithromycin pharmaceutical formulation.

What product did Andrx seek to copy?

Andrx sought approval for a generic extended-release clarithromycin product corresponding to Abbott’s Biaxin XL.

Was Abbott v. Andrx a Paragraph IV case?

Yes. Andrx’s ANDA included a Paragraph IV certification challenging Abbott’s listed patent, and Abbott filed suit under the Hatch-Waxman patent-litigation framework.

Did the case involve Humira or a biosimilar?

No. The dispute involved Biaxin XL and clarithromycin, a small-molecule antibiotic. It did not involve Humira, a biologic, or a biosimilar application.

What was the main commercial issue?

The main issue was whether Andrx could obtain FDA approval and launch a generic extended-release clarithromycin product before the ’620 patent expired or was otherwise resolved.

References

1. U.S. Food and Drug Administration. (2005-2010). Approved drug products with therapeutic equivalence evaluations [Orange Book].
2. Abbott Laboratories v. Andrx Pharmaceuticals, Inc., 452 F.3d 1331 (Fed. Cir. 2006).
3. Abbott Laboratories v. Andrx Pharmaceuticals, Inc., 473 F.3d 1196 (Fed. Cir. 2007).
4. U.S. Patent No. 6,551,620. (2003). Extended release pharmaceutical formulation. U.S. Patent and Trademark Office.
5. Drug Price Competition and Patent Term Restoration Act, Pub. L. No. 98-417, 98 Stat. 1585 (1984).